BGI Genomics Co., Ltd. engages in the provision of genomic sequencing services and proteomic services to academic institutions, pharmaceutical companies, health care providers and other organizations in China and internationally. The company offers DNA sequencing services covering whole genome sequencing, plant/animal whole genome sequencing, exome sequencing, de novo sequencing, and metagenomic sequencing; and mass spectrometry services, such as proteomic services and biologics characterization services. It also provides diagnostics and precision medicine, such as COVID-19 solutions, partnership opportunities, infectious diseases, and oncology services. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. The company was founded in 1999 and is headquartered in Shenzhen, China. BGI Genomics Co., Ltd. operates as a subsidiary of BGI Group.
Metrics to compare | 300676 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship300676PeersSector | |
|---|---|---|---|---|
P/E Ratio | −22.3x | −9.4x | −0.6x | |
PEG Ratio | 0.03 | −0.13 | 0.00 | |
Price/Book | 1.9x | 3.5x | 2.6x | |
Price / LTM Sales | 4.8x | 7.6x | 3.3x | |
Upside (Analyst Target) | 24.5% | 29.3% | 40.3% | |
Fair Value Upside | Unlock | 6.8% | 3.9% | Unlock |